Compare NHTC & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NHTC | AZTR |
|---|---|---|
| Founded | 1988 | 2014 |
| Country | United States | United States |
| Employees | 120 | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0M | 7.9M |
| IPO Year | 1999 | 2023 |
| Metric | NHTC | AZTR |
|---|---|---|
| Price | $0.98 | $0.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 95.7K | ★ 628.4K |
| Earning Date | 11-04-2026 | 11-11-2026 |
| Dividend Yield | ★ 43.15% | N/A |
| EPS Growth | N/A | ★ 5.06 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $39,776,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.89 | $0.10 |
| 52 Week High | $4.68 | $1.09 |
| Indicator | NHTC | AZTR |
|---|---|---|
| Relative Strength Index (RSI) | 34.48 | 31.49 |
| Support Level | $0.89 | $0.10 |
| Resistance Level | $1.95 | $0.15 |
| Average True Range (ATR) | 0.09 | 0.01 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 45.83 | 5.06 |
Natural Health Trends Corp is an international direct-selling and e-commerce company. It offers a line of products such as Wellness, Herbal, Beauty, Lifestyle, and Home. Wellness products include targeted nutrition for joint health, antioxidant support, digestive health, heart health, and vision health. Herbal products include anti-aging and hydrating cleansers, creams, lotions, serums, and toners. Lifestyle products improve the overall quality of life and support active, physical, and healthy lifestyles. Home products are designed to create a clean and natural living environment for the home. It generates a majority of its revenue from Hong Kong and the rest from China, Taiwan, Japan, the United States, and other regions.
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.